Breast Cancer

Recorded Presentation from the NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer

It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.

NCCN Tumor Boards: Treatment Selection Strategies and Barriers to Clinical Care in Metastatic Breast Cancer

Clinicians need to understand the diverse and evolving SDOH landscape, especially as it relates to clinical trial access for individuals with metastatic breast cancer (mBC), and they need to consider potential strategies to address SDOH to ensure equitable care and improve overall outcomes for patients with mBC.

NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer

It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.

Updates to the Management of HR-Positive, HER2-Negative Breast Cancer

The treatment landscape of HR-positive, HER2-negative breast cancer is evolving constantly in the adjuvant as well as the metastatic settings. The decision-making process of treatment selection should involve careful consideration of the available evidence and a detailed discussion of the associated benefits and risks with patients. Staying up to date with the available treatment options is important to integrate new evidence-based data into clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.

Variations in Breast Cancer Screening Recommendations

Breast screening is performed in individuals without any signs or symptoms of breast cancer so that disease can be detected as early as possible, with the goal of decreasing the overall treatment needed and reducing morbidity and mortality rates.

Team-Based Case Review: Breast Cancer

As a result of the therapeutic advances and clinical research affecting the management of patients with cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.

Cardiovascular Health After Breast Cancer Treatment

Breast cancer survivors are at increased risk of cardiovascular disease (CVD) and death from cardiovascular complications. Therefore, CVD risk assessment and counseling on CVD risk factor management are recommended for all cancer survivors throughout the survivorship continuum.

Issues with Sexuality and Sexual Function in Patients with Breast Cancer

Addressing sexual health is an essential step during the treatment of breast cancer. Healthcare providers should discuss with patients the potential changes in sexual function and sexuality related to cancer treatment as well as the measures that are available to overcome these challenges.

Advances in the Management of Metastatic Breast Cancer with SABCS Updates

This activity covers the following presentations:

Advances in the Management of HR-Positive Metastatic Breast Cancer with SABCS Updates
Advances in the Management of HER2-Positive Metastatic Breast Cancer with SABCS Updates

Locoregional Management of Breast Cancer with SABCS Updates